Santhera gets FDA nod for Agamree to treat Duchenne muscular dystrophy
The FDA approval was based on the findings from the phase 2b VISION-DMD trial in which Agamree met…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
30 Oct 23
The FDA approval was based on the findings from the phase 2b VISION-DMD trial in which Agamree met…
30 Oct 23
The US health regulator has asked the consumers not to purchase and immediately stop using the products over…
30 Oct 23
RVO is the third indication for Vabysmo, in addition to neovascular or ‘wet’ age-related macular degeneration and diabetic…
30 Oct 23
The MAA is supported by positive data from the Phase 3 MIRASOL trial of ELAHERE in platinum-resistant ovarian…
26 Oct 23
The ACIP panel voted to recommend that 18 years and older individuals with certain risk factors should be…
25 Oct 23
The approval was based on the data from the Phase 1, multicentre study of IDH1-mutated R/R MDS patients…
25 Oct 23
The governing body has launched a European Voluntary Solidarity Mechanism, will create a union list of critical medicines,…
24 Oct 23
The enlarged company after the subsequent merger is anticipated to operate under the name NAYA Biosciences and will…
24 Oct 23
The approval is supported by the safety and efficacy data from the Phase 3 HERO trial of Orgovyx…
24 Oct 23
Certa previously announced positive top-line results from a Phase 2 study which indicated that treatment with FT011 for…